Entera Bio Ltd
ENTX1.770USD
-0.170-8.76%
收盤 12/19, 16:00（美東）報價延遲15分鐘
80.83M總市值
虧損本益比TTM
關於 Entera Bio Ltd 公司
Entera Bio Ltd is an Israel-based clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in areas with unmet medical need and where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.
Entera Bio Ltd簡介
公司代碼ENTX
公司名稱Entera Bio Ltd
上市日期Jun 28, 2018
CEOToledano (Miranda Jayne)
員工數量18
證券類型Ordinary Share
年結日Jun 28
公司地址Hadassah / Jerusalem Bio
城市JERUSALEM
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Israel
郵編9112002
電話97225327151
網址https://enterabio.com/
公司代碼ENTX
上市日期Jun 28, 2018
CEOToledano (Miranda Jayne)
Entera Bio Ltd公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Gerald M. (Jerry) Lieberman
Mr. Gerald M. (Jerry) Lieberman
Independent Chairman of the Board
Independent Chairman of the Board
324.96K
--
Ms. Miranda Jayne Toledano
Ms. Miranda Jayne Toledano
Chief Executive Officer, Director
Chief Executive Officer, Director
291.45K
+163.16%
Mr. Sean Ellis
Mr. Sean Ellis
Independent Director
Independent Director
134.73K
--
Ms. Haya Taitel
Ms. Haya Taitel
Independent Director
Independent Director
64.65K
--
Mr. Yonatan Malca
Mr. Yonatan Malca
Independent Director
Independent Director
47.26K
--
Mr. Gerald M. (Jerry) Ostrov
Mr. Gerald M. (Jerry) Ostrov
Independent Director
Independent Director
46.94K
--
Mr. Ron Abraham Mayron
Mr. Ron Abraham Mayron
Independent Director
Independent Director
--
--
Ms. Dana Yaacov-Garbeli
Ms. Dana Yaacov-Garbeli
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Roger J. Garceau, M.D.
Dr. Roger J. Garceau, M.D.
Director
Director
--
--
Dr. Hillel Galitzer
Dr. Hillel Galitzer
Chief Operating Officer
Chief Operating Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Gerald M. (Jerry) Lieberman
Mr. Gerald M. (Jerry) Lieberman
Independent Chairman of the Board
Independent Chairman of the Board
324.96K
--
Ms. Miranda Jayne Toledano
Ms. Miranda Jayne Toledano
Chief Executive Officer, Director
Chief Executive Officer, Director
291.45K
+163.16%
Mr. Sean Ellis
Mr. Sean Ellis
Independent Director
Independent Director
134.73K
--
Ms. Haya Taitel
Ms. Haya Taitel
Independent Director
Independent Director
64.65K
--
Mr. Yonatan Malca
Mr. Yonatan Malca
Independent Director
Independent Director
47.26K
--
Mr. Gerald M. (Jerry) Ostrov
Mr. Gerald M. (Jerry) Ostrov
Independent Director
Independent Director
46.94K
--
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 11月17日 週一
更新時間: 11月17日 週一
持股股東
股東類型
持股股東
持股股東
佔比
Knoll Capital Management, LLC
12.83%
OPKO Health Inc
8.43%
D.N.A Biomedical Solutions, Ltd.
8.14%
Centillion Fund Inc
5.23%
Point72 Asset Management, L.P.
2.57%
其他
62.81%
持股股東
持股股東
佔比
Knoll Capital Management, LLC
12.83%
OPKO Health Inc
8.43%
D.N.A Biomedical Solutions, Ltd.
8.14%
Centillion Fund Inc
5.23%
Point72 Asset Management, L.P.
2.57%
其他
62.81%
股東類型
持股股東
佔比
Corporation
21.80%
Hedge Fund
17.54%
Individual Investor
2.41%
Investment Advisor/Hedge Fund
1.41%
Investment Advisor
0.66%
Family Office
0.31%
Research Firm
0.11%
Venture Capital
0.02%
其他
55.74%
機構持股
更新時間: 12月8日 週一
更新時間: 12月8日 週一
報告期間
機構數
持股數
持股佔比
持股變動
2025Q4
31
10.02M
22.66%
--
2025Q3
32
10.02M
22.66%
-49.40K
2025Q2
33
10.07M
22.72%
-152.10K
2025Q1
34
10.22M
23.69%
-537.14K
2024Q4
32
7.49M
20.14%
+518.60K
2024Q3
30
5.32M
15.79%
+29.98K
2024Q2
29
5.29M
11.96%
+1.38M
2024Q1
26
4.27M
12.41%
-130.45K
2023Q4
26
4.07M
8.01%
+1.48M
2023Q3
27
2.59M
10.16%
+9.25K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Knoll Capital Management, LLC
5.88M
12.88%
--
--
Jun 30, 2025
OPKO Health Inc
3.87M
8.46%
+180.00K
+4.88%
May 08, 2025
D.N.A Biomedical Solutions, Ltd.
3.73M
8.17%
--
--
May 08, 2025
Centillion Fund Inc
2.40M
5.25%
--
--
May 08, 2025
Point72 Asset Management, L.P.
2.70M
5.91%
--
--
Jun 30, 2025
Schonfeld Strategic Advisors LLC
604.52K
1.32%
+5.37K
+0.90%
Jun 30, 2025
Lieberman (Gerald M)
324.96K
0.71%
--
--
May 08, 2025
Toledano (Miranda Jayne)
291.45K
0.64%
+180.70K
+163.16%
Jul 16, 2025
Parkman Healthcare Partners LLC
355.82K
0.78%
-83.81K
-19.06%
Jun 30, 2025
查看更多
持股ETF
機構名稱
佔比
暫無數據
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
常見問題
Entera Bio Ltd的前五大股東是誰？
Entera Bio Ltd的前五大股東如下：
Knoll Capital Management, LLC持有股份：5.88M佔總股份比例：12.88%。
OPKO Health Inc持有股份：3.87M佔總股份比例：8.46%。
D.N.A Biomedical Solutions, Ltd.持有股份：3.73M佔總股份比例：8.17%。
Centillion Fund Inc持有股份：2.40M佔總股份比例：5.25%。
Point72 Asset Management, L.P.持有股份：2.70M佔總股份比例：5.91%。
Knoll Capital Management, LLC持有股份：5.88M佔總股份比例：12.88%。
OPKO Health Inc持有股份：3.87M佔總股份比例：8.46%。
D.N.A Biomedical Solutions, Ltd.持有股份：3.73M佔總股份比例：8.17%。
Centillion Fund Inc持有股份：2.40M佔總股份比例：5.25%。
Point72 Asset Management, L.P.持有股份：2.70M佔總股份比例：5.91%。
Entera Bio Ltd的前三大股東類型是什麼？
Entera Bio Ltd 的前三大股東類型分別是：
Knoll Capital Management, LLC
OPKO Health Inc
D.N.A Biomedical Solutions, Ltd.
Knoll Capital Management, LLC
OPKO Health Inc
D.N.A Biomedical Solutions, Ltd.
有多少機構持有Entera Bio Ltd(ENTX)的股份？
截至2025Q4，共有31家機構持有Entera Bio Ltd的股份，合計持有的股份價值約為10.02M，占公司總股份的22.66% 。與2025Q3相比，機構持股有所增加，增幅為-0.00%。
哪個業務部門對Entera Bio Ltd的收入貢獻最大？
在--，--業務部門對Entera Bio Ltd的收入貢獻最大，創收--，占總收入的--% 。
